In the alliance, Galapagos will apply its target discovery platform to discover novel COPD targets. Galapagos will be responsible for the discovery and development of new small molecule candidate drugs against these targets. Roche will have an exclusive option to license each small molecule program after either clinical candidate selection or completion of phase I clinical trials.
In addition, Roche has an exclusive option to license the COPD targets for the discovery and development of antibodies against these targets. Upon exercise of each option, Roche will be responsible for the further development and commercialization.
As per the agreement, Galapagos has received a research access payment of E6m from Roche. Galapagos is also eligible to receive discovery, development, regulatory and sales milestone payments that could potentially exceed E400m, plus royalties upon commercialization of any products covered in the agreement.
Onno van de Stolpe, CEO of Galapagos, said: “This alliance with Roche on discovering novel COPD targets demonstrates the versatility of Galapagos’ target discovery platform in identifying novel targets across a wide range of therapeutic areas. We are excited that this collaboration will focus on both antibodies and small molecules as potential drugs for COPD. Roche’s vast experience in developing and commercializing antibodies makes it the perfect partner for this combined approach.”
Satwant Narula, head of discovery for the inflammation area of Roche, said: “Galapagos’ track record in discovering novel therapeutic targets and its drug discovery expertise make it an ideal partner for our COPD discovery program. We feel confident that this alliance will bring new mode of action drugs for COPD into the clinic for Roche.”